Table 1.
Baseline characteristics by pre-transplant sarcopenia status.
| All patients (n=146) | Normal (n=66) | Sarcopenic (n=80) | p-value | |
|---|---|---|---|---|
| Age (median, range) | 60.7 (50–78.7) | 58.9 (50–75.3) | 61.5 (50.2–78.7) | 0.09 |
| Sex (n, %) | 0.046 | |||
| Male | 102 (69.9) | 52 (78.8) | 50 (62.5) | |
| Female | 44 (30.1) | 14 (21.2) | 30 (37.5) | |
| Lymphoma (n, %) | 0.73 | |||
| Hodgkin's | 8 (5.5) | 3 (4.6) | 5 (6.3) | |
| Non-Hodgkin's | 138 (94.5) | 63 (95.5) | 75 (93.8) | |
| Disease risk index (n, %) | >0.99 | |||
| Low/intermediate | 142 (97.3) | 64 (97) | 78 (92.5) | |
| High/very high | 4 (2.7) | 2 (3) | 2 (2.5) | |
| HCT-CI (n, %) | >0.99 | |||
| 0–2 | 81 (55.5) | 37 (56.1) | 44 (55) | |
| ≥3 | 65 (44.5) | 29 (43.9) | 36 (45) | |
| Stem cell source | >0.99 | |||
| Peripheral blood | 136 (93.2) | 62 (93.9) | 74 (92.5) | |
| Bone marrow | 10 (6.8) | 4 (6.1) | 6 (7.5) | |
| Donor type | 0.84 | |||
| Matched | 118 (80.8) | 54 (81.8) | 64 (80) | |
| Alternative | 28 (19.2) | 12 (18.2) | 16 (20) | |
| Patient CMV | 0.07 | |||
| Positive | 66 (45.2) | 24 (36.4) | 42 (52.5) | |
| Negative | 80 (54.8) | 42 (63.6) | 38 (47.5) | |
| ADL/IADL | 0.54 | |||
| Impaired | 11 (7.5) | 5 (7.6) | 6 (7.5) | |
| Normal | 89 (61) | 37 (56.1) | 52 (65) | |
| Missing | 46 (31.5) | 24 (36.4) | 22 (27.5) | |
| PIM user | >0.99 | |||
| Yes | 70 (47.9) | 32 (48.5) | 38 (47.5) | |
| No | 76 (52.1) | 34 (51.5) | 42 (52.5) | |
| Depression | 0.66 | |||
| Yes | 24 (16.4) | 12 (18.2) | 12 (15) | |
| No | 122 (83.6) | 54 (81.8) | 68 (85) | |
| Prior fall | 0.66 | |||
| Yes | 24 (16.4) | 12 (18.2) | 12 (15) | |
| No | 122 (83.6) | 54 (81.8) | 68 (85) | |
| Weight loss | 0.09 | |||
| Yes | 14 (9.6) | 3 (4.5) | 11 (13.8) | |
| No | 132 (90.4) | 63 (95.5) | 69 (86.3) | |
Abbreviations: HCT-CI, Hematopoietic cell transplantation-comorbidity index; CMV, Cytomegalovirus; ADL, Activities of daily living; IADL, Instrumental activities of daily living; PIM, Potentially inappropriate medication.